Inclusion Criteria: | |
---|---|
· Must be 18 years of age or older | |
· Diagnosed with Type 1 or Type 2 diabetes | |
· Recent HbA1c #62;7.5% (measured within the last 6 weeks at local laboratory) | |
· Using MDI therapy for at least 6 months consisting of 1–2 injections per day of long-acting basal insulin (Lantus® or Detemir®) and at least 2 injections per day of regular or rapid-acting analog insulin for meal coverage | |
· Participant adjusts meal insulin doses based on carbohydrate content of meals | |
· Participant with Type 2 diabetes may be on stable metformin therapy (therapy unchanged during 3 months prior to study) | |
· Participant has been in Investigator's practice for at least 3 months; however may have been seen by another physician in the practice | |
· Participant has completed carbohydrate (CHO) training within the last 2 years | |
Exclusion Criteria: | |
· On a therapy regimen that conflicts with study: | |
· NPH or pre-mixed insulin | |
· Oral anti-diabetic agents, with the exception of metformin | |
· Injectable anti-diabetic agents other than long-acting insulin and rapid-acting insulin analogs or regular insulin (e.g., fixed dose therapy) | |
· Use of sliding scale insulin therapy that determines insulin dosages based exclusively on specific bG results | |
· Participated in another interventional trial within 6 weeks prior to study | |
· Diagnosed with any clinically significant infectious disease or major organ system disease, such as gastroparesis or renal disease (at Investigator's discretion) | |
· Used systemic oral or inhaled steroids for more than 7 days within the last 3 months | |
· On Chemotherapy or Radiation therapy (self-reported) | |
· Pregnant or lactating or is currently planning a pregnancy |